The Form 4 filing lists November 10, 2026, as both the sale date and the filing date. Form 4 is an SEC report that discloses changes in an insider's stock ownership. Erica Rossitto serves as senior vice president and chief nurse executive at HCA Healthcare.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-10 |
| Date of Latest Transaction | 2026-11-10 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 3,500 |
| Price | $505.81 |
| Total Transaction Value | $1,770,335.35 |
| Insider | |
| Ticker Symbol | HCA |
| Company | HCA Healthcare, Inc. |
| Insider Name | Rossitto Erica |
| Insider Title | SVP & Chief Nurse Executive |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 13,426 |
| Position Size Change | 20.68% |
| Filing | |
| Filing Date | 2026-11-10 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of HCA shares, reported under transaction code S. Erica Rossitto sold shares in one reported transaction. The available details do not state why she made the sale.
What was the average price of the transaction?
The average sale price was $505.8101 per share. Rounded to the nearest cent, that is $505.81, the price shown in the transaction details.
How did this transaction affect the insider's holdings?
She sold 3,500 shares and reported 13,426 shares owned afterward. Those figures imply 16,926 shares before the sale within the reported holding. The shares sold made up 20.68% of that earlier balance.
What's the total transaction value?
The total value was $1,770,335.35 for the single reported sale. This amount covers all 3,500 shares sold, rather than the price of one share.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement for this sale. Filing footnotes were not provided, so further terms or plan details remain unknown. The available information does not rule out other circumstances.
For research purposes only; not investment advice.